Source: http://www.google.com/patents/US8119680?dq=5,687,325
Timestamp: 2016-08-23 21:30:05
Document Index: 221815582

Matched Legal Cases: ['Application No. 2525547', 'Application No. 04752297', 'Application No. 200507305', 'Application No. 2004247013', 'Application No. 2006', 'Application No. 4753', 'Application No. 04752297']

Patent US8119680 - α-Haloketone derivatives of imidazolyl-substituted aromatic compounds and ... - Google PatentsSearch Images Maps Play YouTube News Gmail Drive More »Sign inPatentsNovel compounds, compositions, and kits are provided. Methods of modulating Aβ levels, and methods of treating a disease associated with aberrant Aβ levels are also provided....http://www.google.com/patents/US8119680?utm_source=gb-gplus-sharePatent US8119680 - α-Haloketone derivatives of imidazolyl-substituted aromatic compounds and compounds prepared therefromAdvanced Patent SearchPublication numberUS8119680 B2Publication typeGrantApplication numberUS 12/875,935Publication dateFeb 21, 2012Filing dateSep 3, 2010Priority dateMay 14, 2003Fee statusLapsedAlso published asCA2525547A1, CA2525547C, CN102584813A, CN102584813B, EP1628666A2, EP1628666A4, EP1628666B1, US7244739, US7781442, US7799808, US8017629, US20050070538, US20070249833, US20070260058, US20100324032, US20100331551, WO2004110350A2, WO2004110350A3Publication number12875935, 875935, US 8119680 B2, US 8119680B2, US-B2-8119680, US8119680 B2, US8119680B2InventorsSoan Cheng, Daniel D Comer, Long Mao, Guity P Balow, David PleynetOriginal AssigneeNeurogenetic Pharmaceuticals, Inc.Export CitationBiBTeX, EndNote, RefManPatent Citations (80), Non-Patent Citations (41), Referenced by (3), Classifications (29), Legal Events (3) External Links: USPTO, USPTO Assignment, Espacenetα-Haloketone derivatives of imidazolyl-substituted aromatic compounds and compounds prepared therefrom
Patent CitationsCited PatentFiling datePublication dateApplicantTitleUS3710795Sep 29, 1970Jan 16, 1973Alza CorpDrug-delivery device with stretched, rate-controlling membraneUS4044126Jul 9, 1976Aug 23, 1977Allen & Hanburys LimitedSteroidal aerosol compositions and process for the preparation thereofUS4328245Feb 13, 1981May 4, 1982Syntex (U.S.A.) Inc.Carbonate diester solutions of PGE-type compoundsUS4358603Apr 16, 1981Nov 9, 1982Syntex (U.S.A.) Inc.Acetal stabilized prostaglandin compositionsUS4364923Apr 30, 1981Dec 21, 1982Allen & Hanburs LimitedChemical compoundsUS4409239Jan 21, 1982Oct 11, 1983Syntex (U.S.A.) Inc.Propylene glycol diester solutions of PGE-type compoundsUS4410545May 10, 1982Oct 18, 1983Syntex (U.S.A.) Inc.Carbonate diester solutions of PGE-type compoundsUS4414209Jun 13, 1977Nov 8, 1983Allen & Hanburys LimitedMicronized aerosol steroidsUS4766213Jan 16, 1987Aug 23, 1988Merck Patent Gesellschaft Mit Beschrankter Haftung1,4-dihydropyridinesUS5033252Jul 30, 1990Jul 23, 1991Entravision, Inc.Method of packaging and sterilizing a pharmaceutical productUS5052558Jul 27, 1990Oct 1, 1991Entravision, Inc.Packaged pharmaceutical productUS5323907Mar 15, 1993Jun 28, 1994Multi-Comp, Inc.Child resistant package assembly for dispensing pharmaceutical medicationsUS5387742Jun 17, 1991Feb 7, 1995Scios Nova Inc.Transgenic mice displaying the amyloid-forming pathology of alzheimer's diseaseUS5594010Jun 17, 1994Jan 14, 1997Bayer AktiengesellschaftSubstituted monopyridylmethyl derivativesUS5612486Nov 1, 1993Mar 18, 1997Athena Neurosciences, Inc.Transgenic animals harboring APP allele having swedish mutationUS5672805Jul 18, 1991Sep 30, 1997The Regents Of The University Of CaliforniaTransgenic mice expressing the neurotoxic C-terminus of β-amyloid precursor proteinUS5709874Jun 3, 1996Jan 20, 1998Emory UniversityDevice for local drug delivery and methods for using the sameUS5759542Aug 5, 1994Jun 2, 1998New England Deaconess Hospital CorporationCompositions and methods for the delivery of drugs by platelets for the treatment of cardiovascular and other diseasesUS5811633Jun 7, 1995Sep 22, 1998Wadsworth; SamuelTransgenic mouse expressing APP770US5840674Aug 1, 1996Nov 24, 1998Oregon Health Sciences UniversityCovalent microparticle-drug conjugates for biological targetingUS5850003Jan 22, 1997Dec 15, 1998Athena NeurosciencesTransgenic rodents harboring APP allele having swedish mutationUS5860957Feb 7, 1997Jan 19, 1999Sarcos, Inc.Multipathway electronically-controlled drug delivery systemUS5900252Nov 6, 1992May 4, 1999Eurand International S.P.A.Method for targeted and controlled release of drugs in the intestinal tract and more particularly in the colonUS5948433Aug 21, 1997Sep 7, 1999Bertek, Inc.Transdermal patchUS5972366Sep 17, 1996Oct 26, 1999The Unites States Of America As Represented By The Secretary Of The ArmyDrug releasing surgical implant or dressing materialUS5983134Jun 12, 1998Nov 9, 1999Electromagnetic Bracing Systems Inc.Electrophoretic cuff apparatus drug delivery systemUS5985307Dec 2, 1997Nov 16, 1999Emory UniversityDevice and method for non-occlusive localized drug deliveryUS5985317Sep 6, 1996Nov 16, 1999Theratech, Inc.Pressure sensitive adhesive matrix patches for transdermal delivery of salts of pharmaceutical agentsUS6004534Apr 18, 1997Dec 21, 1999Massachusetts Institute Of TechnologyTargeted polymerized liposomes for improved drug deliveryUS6010715Oct 21, 1997Jan 4, 2000Bertek, Inc.Transdermal patch incorporating a polymer film incorporated with an active agentUS6024975Nov 12, 1996Feb 15, 2000Americare International Diagnostics, Inc.Method of transdermally administering high molecular weight drugs with a polymer skin enhancerUS6037521Nov 14, 1994Mar 14, 2000Hoechst Japan LimitedTransgenic mouse expressing an β-Amyloid transgeneUS6039975Sep 20, 1996Mar 21, 2000Hoffman-La Roche Inc.Colon targeted delivery systemUS6048736Dec 30, 1998Apr 11, 2000Kosak; Kenneth M.Cyclodextrin polymers for carrying and releasing drugsUS6060082Apr 18, 1997May 9, 2000Massachusetts Institute Of TechnologyPolymerized liposomes targeted to M cells and useful for oral or mucosal drug deliveryUS6071495Oct 2, 1997Jun 6, 2000Imarx Pharmaceutical Corp.Targeted gas and gaseous precursor-filled liposomesUS6120751Sep 8, 1997Sep 19, 2000Imarx Pharmaceutical Corp.Charged lipids and uses for the sameUS6131570Jun 30, 1998Oct 17, 2000Aradigm CorporationTemperature controlling device for aerosol drug deliveryUS6139865Oct 1, 1997Oct 31, 2000Eurand America, Inc.Taste-masked microcapsule compositions and methods of manufactureUS6167301Aug 29, 1995Dec 26, 2000Flower; Ronald J.Iontophoretic drug delivery device having high-efficiency DC-to-DC energy conversion circuitUS6184435Jun 7, 1995Feb 6, 2001Advanced Research And Technology InstituteTransgenic mouse expressing APP770-V717FUS6187797Dec 22, 1997Feb 13, 2001Dupont Pharmaceuticals CompanyPhenyl-isoxazoles as factor XA InhibitorsUS6187992Mar 11, 1999Feb 13, 2001Merck & Co., Inc.Transgenic mouse having a disrupted amyloid precursor protein geneUS6211428Aug 28, 1995Apr 3, 2001Merck & Co., Inc.Transgenic mouse expressing a familial form of human amyloid precursor proteinUS6253872May 23, 1997Jul 3, 2001Gmundner Fertigteile Gesellschaft M.B.H & Co., KgTrack soundproofing arrangementUS6256533Jun 9, 1999Jul 3, 2001The Procter & Gamble CompanyApparatus and method for using an intracutaneous microneedle arrayUS6261595Feb 29, 2000Jul 17, 2001Zars, Inc.Transdermal drug patch with attached pocket for controlled heating deviceUS6267983Oct 26, 1998Jul 31, 2001Bando Chemical Industries, Ltd.Dermatological patch and process for producing thereofUS6271359Apr 14, 1999Aug 7, 2001Musc Foundation For Research DevelopmentTissue-specific and pathogen-specific toxic agents and ribozymesUS6274552Nov 10, 1997Aug 14, 2001Cytimmune Sciences, Inc.Composition and method for delivery of biologically-active factorsUS6316652Jun 6, 1995Nov 13, 2001Kosta SteliouDrug mitochondrial targeting agentsUS6340783Oct 3, 1996Jan 22, 2002University Of WashingtonRodent models of human amyloidosesUS6562817Jan 26, 1999May 13, 2003Shionogi & Co., Ltd.Tricyclic compoundUS20030158199Jan 25, 2002Aug 21, 2003Kylix, B.V.Novel compounds for inhibition of Tie-2USRE28819Apr 16, 1975May 18, 1976Syntex (U.S.A.) Inc.Dialkylated glycol compositions and medicament preparations containing sameEP0219436A2Oct 16, 1986Apr 22, 1987Mitsubishi Kasei CorporationThiazole derivative and leukotriene antagonist containing the same as the effective ingredientsEP1052238A1Jan 26, 1999Nov 15, 2000SHIONOGI &amp; CO., LTD.Novel tricyclic compoundJP2001114690A Title not availableJP2002121597A Title not availableJP2002531503A Title not availableJP2002531504A Title not availableJP2003313176A Title not availableJP2004516507A Title not availableJP2006500325A Title not availableJPH0748369A Title not availableJPH01143856A Title not availableJPH04276551A Title not availableJPS62181277A Title not availableWO1997036898A1Apr 1, 1997Oct 9, 1997Merck & Co., Inc.Inhibitors of farnesyl-protein transferaseWO1999038829A1Jan 26, 1999Aug 5, 1999Shionogi & Co., Ltd.Novel tricyclic compoundWO2000033841A1Dec 7, 1999Jun 15, 2000Smithkline Beecham CorporationMyt1 kinase inhibitorsWO2000033842A1Dec 7, 1999Jun 15, 2000Smithkline Beecham CorporationMyt1 kinase inhibitorsWO2001087845A2May 14, 2001Nov 22, 2001Fujisawa Pharmaceutical Co., Ltd.N-containing heterocyclic compounds and their use as 5-ht antagonistsWO2002050591A1Dec 19, 2001Jun 27, 2002Teradyne, Inc.Methods and apparatus for controlling access to an optical interfaceWO2002083667A2Apr 10, 2002Oct 24, 2002Vertex Pharmaceuticals IncorporatedInhibitors of c-jun n-terminal kinases (jnk) and other protein kinasesWO2003007955A2Jul 22, 2002Jan 30, 2003Cancer Research Technology LimitedBiphenyl apurinic/apyrimidinic site endonuclease inhibitors to treat cancerWO2003032916A2Oct 16, 2002Apr 24, 2003Structural Bioinformatics Inc.Organosulfur inhibitors of tyrosine phosphatasesWO2004002480A1May 27, 2003Jan 8, 2004Novo Nordisk A/SNovel glucagon antagonists/inverse agonistsWO2004016997A1Jun 26, 2003Feb 26, 2004Oxford Magnet TechnologyOil carry-over prevention from helium gas compressorWO2004046120A2Nov 17, 2003Jun 3, 2004Vertex Pharmaceuticals IncorporatedDiaminotriazoles useful as inhibitors of protein kinasesNon-Patent CitationsReference1Canadian Office Action dated Jun. 29, 2010 for Application No. 2525547 .2Dhar et al., A Survey of Cyclic Replacements for the Central Diamide Moiety of Inhibitors of Inosine Monophosphate Dehydrogenase. Bioorganic & Medicinal Chemistry Letters, 12:3125-3128 (2002).3Emilien et al., Prospects for Pharmacological Intervention in Alzheimer Disease, Arch Neuro., 57:176-181 (2000).4European Search Report dated Nov. 7, 2007 for EP Application No. 04752297.4.5Examination Report dated Jan. 30, 2006 for SG Application No. 200507305-1.6Examiner's Report dated Oct. 15, 2009 for AU Application No. 2004247013.7Games et al., Alzheimer-type neuropathology in transgenic mice overexpressing V717F beta-amyloid precursor protein, Nature 373:523-527 (1995).8Games et al., Alzheimer-type neuropathology in transgenic mice overexpressing V717F β-amyloid precursor protein, Nature 373:523-527 (1995).9Hampel et al, Synthese einiger 2-Alkylamino- und 2-Arylamino-4-aryl-thiazole. Journal fur Praktische Chemie, 1968, 38(5-6):320-326.10Harris et al., Discovery and evaluation of 2-Anilino-5-aryloxazoles as a novel class of VEGFR2 kinase inhibitors, Journal of Medicinal Chemistry, Web release Feb. 9, 2005.11International Search Report and Written Opinion dated Dec. 20, 2004 for PCT Application No. PCT/US04/15239.12Japanese Office Action dated Jun. 1, 2010 for Application No. 2006-533094, English Translation.13Joshi et al., Synthesis of Some Substituted Pyrazoles as Possible Antibacterial Agents, J. Indian Chem. Soc., vol. LIV, pp. 1081-1083 (1977).14Joshua et al, Interaction of Thiocarbamides with alpha-Bromoketones: Formation of Substituted 2-Aminothiazoles, Indian Journal of Chemistry, 1973, 11(2):118-119.15Joshua et al, Interaction of Thiocarbamides with α-Bromoketones: Formation of Substituted 2-Aminothiazoles, Indian Journal of Chemistry, 1973, 11(2):118-119.16Klunk et al., Imaging Abeta Plaques in Living Transgenic Mice with Multiphoton Microscopy and Methoxy-X04, a Systematically Administered Congo Red Derivative, J. Neuropathol. Exp. Neurol., 61:797-805 (2002).17Klunk et al., Imaging Aβ Plaques in Living Transgenic Mice with Multiphoton Microscopy and Methoxy-X04, a Systematically Administered Congo Red Derivative, J. Neuropathol. Exp. Neurol., 61:797-805 (2002).18 *Lubisch et al. CAS: 135: 166828, 2001.19Mathis et al., A Lipophilic Thioflavin-T Derivative for Positron emission tomography (PET) Imaging of Amyloid in Brain, Bioorg. Med. Chem. Lett., 12:295-298 (2002).20 *Mishina et al. CAS: 123:83361, 1995.21Nagatomi et al, Studies on the Anti-inflammatory Activity and Ulcerogenic Adverse Effect of Thiazole Derivatives, Especially 2-Amino-thiazoleacetic Acid Derivatives, Arzneiitte1-Forschung Druq Research, 1984, 34(5):599-603.22Neve et al., Transgenic Mice Expressing APP-C100 in the Brain, Neurobiol. Aging, 17:191-203 (1996).23Office Action dated Sep. 22, 2006 for IN Application No. 4753/DELNP/2005.24Official Action for European Application No. 04752297.4 dated Nov. 30, 2010.25Pruitt et al., CAS: 134:375528 (2001).26Reddy et al, Activity of Acryloyl Thaiazoles, Thiazolyl Aminopyrimidines and Thiazolyl Thiopyrmidines on Aspergillus flavus Link, ex Fries In Vitro, Indian Bot. Reptr 4(2):144-147 (1985).27Schumann et al, Synthesis and Characterization of Some Heterocyclic Analogues of N.N′-Perarylated Phenylen-1,4-diamines and Benzidines as a New Class of Hole Transport materials, Synthesis, 2002, No. 9, pp. 1268-1276.28Schumann et al, Synthesis and Characterization of Some Heterocyclic Analogues of N.N'-Perarylated Phenylen-1,4-diamines and Benzidines as a New Class of Hole Transport materials, Synthesis, 2002, No. 9, pp. 1268-1276.29US Notice of Allowance dated Apr. 16, 2010 for U.S. Appl. No. 11/779,249.30US Notice of Allowance dated Apr. 29, 2011 in U.S. Appl. No. 12/861,782.31US Notice of Allowance dated Feb. 6, 2007 for U.S. Appl. No. 10/846,841.32US Notice of Allowance dated May 5, 2010 for U.S. Appl. No. 11/765,397.33US Office Action dated Dec. 2, 2009 for U.S. Appl. No. 11/779,249.34US Office Action dated Dec. 30, 2009 for U.S. Appl. No. 11/765,397.35US Office Action dated Jun. 18, 2009 for U.S. Appl. No. 11/765,397.36US Office Action dated May 22, 2009 for U.S. Appl. No. 11/779,249.37US Office Action dated Oct. 16, 2006 for U.S. Appl. No. 10/846,941.38Wiltfang et al., Elevation of beta-Amyloid Peptide 2-42 in Sporadic and Familial Alzheimer's Disease and Its Generation in PS1 Knockout Cells, J. Biol. Chem., 276:42645-42657 (2001).39Wiltfang et al., Elevation of β-Amyloid Peptide 2-42 in Sporadic and Familial Alzheimer's Disease and Its Generation in PS1 Knockout Cells, J. Biol. Chem., 276:42645-42657 (2001).40Written Opinion dated Jul. 4, 2006 for SG App. No. 200507305-1.41Written Opinion dated May 2, 2007 for SG App. No. 200507305-1.* Cited by examinerReferenced byCiting PatentFiling datePublication dateApplicantTitleUS8865754Mar 1, 2012Oct 21, 2014Proteotech Inc.Compounds for the treatment of neurodegenerative diseasesUS8901309Sep 1, 2011Dec 2, 2014Takeda Pharmaceutical Company LimitedFused triazoles for the treatment or prophylaxis of mild cognitive impairmentUS9403815Jun 24, 2011Aug 2, 2016The Regents Of The University Of CaliforniaCompounds and uses thereof in modulating levels of various amyloid beta peptide alloformsClassifications U.S. Classification514/399, 548/341.1International ClassificationA61K31/415, A61K31/425, A61K31/40, A61K31/53, A61K31/505, A61K31/497, A61K31/535, C07D277/42, C07D417/04, C07D417/14, C07D277/04, A61K31/50, C07D417/10, C07D413/00, C07D233/54, A61K, C07D417/12Cooperative ClassificationC07D277/42, C07D417/04, C07D417/10, C07D417/12, C07D417/14European ClassificationC07D417/12, C07D277/42, C07D417/10, C07D417/14, C07D417/04Legal EventsDateCodeEventDescriptionOct 2, 2015REMIMaintenance fee reminder mailedFeb 21, 2016LAPSLapse for failure to pay maintenance feesApr 12, 2016FPExpired due to failure to pay maintenance feeEffective date: 20160221RotateOriginal ImageGoogle Home - Sitemap - USPTO Bulk Downloads - Privacy Policy - Terms of Service - About Google Patents - Send FeedbackData provided by IFI CLAIMS Patent Services